Washington Mesothelioma Victims Center Urges a Power Plant Worker with Mesothelioma in Washington State to Call Attorney Erik Karst of Karst von Oiste-Get Much Better Compensation Results-That Might be Millions einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
NEW YORK (AP) Despite its world-class medical system and its vaunted Centers for Disease Control and Prevention, the U.S. fell behind in the race to dete
US Races to Catch Up in Effort to Detect Mutant Viruses ohiostandard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ohiostandard.com Daily Mail and Mail on Sunday newspapers.
With COVID-19 vaccine in short supply, confusion abounds over second shots By Sandi Doughton, The Seattle Times
Published: February 5, 2021, 10:30am
Share:
At 71 years old, Lisa Soli was delighted to snag a coveted COVID-19 vaccine during a clinic last month at Overlake Medical Center in Bellevue. But when the retired educator asked about her second dose, the nurse told her they weren’t scheduling boosters and wished her luck finding one.
Soli has been searching ever since.
“You just have to get lucky, and it shouldn’t be that way,” she said. “This is critical life-and-death stuff for those of us over 65.”
Phase 1 clinical trial of novel HIV vaccine approach shows promising results
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well. With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens.